Role of Melatonin in the Prevention of Breast Cancer in Patients With Cystic Breast Disease
Abstract
Melatonin and breast cyst fluids (BCFs) both exert antiproliferative effects on breast cancer cells that may be mediated by growth factors. Our research was the first to identify melatonin in BCF and we hypothesize that it is responsible for BCF's antiproliferative properties. The primary objectives of this study are to establish a clinical BCF sample bank among patients with gross cystic breast disease in order to study the relationship between this disease, melatonin and related growth agents in BCF, and breast cancer risk. A laboratory effort will use BCF samples to elucidate the contribution of melatonin and related growth agents (EGP, TGF-beta, DHEA-S) to the oncostatic effects of BCFs in the MCF-7 human breast cancer cell model. Our progress to date includes the establishment of informed consent procedures and a BCF sample bank. Patient enrollment and BCF sample collection are on-going. Cell culture experiments have confirmed that physiological melatonin levels inhibit MCF-7 cell growth. We have also performed baseline melatonin, sodium, potassium, and TGF-beta measurements in BCF. Out of 17 subtasks specified in our Statement of Work, 8 have either been completed or were initiated in year 1 and will remain on-going as patient enrollment progresses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA388220
Entities
People
- Robert L. Wells
Organizations
- Colorado State University